‘LDL-C’ = LDL-C + Lp(a)-C

• The interactions of Lipoprotein(a) with common cardiovascular risk factors in cardiovascular disease risk: evidence based on the UK Biobank

  2025 American Journal of Preventive Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access

  6

  citations
• Developing an SI-traceable Lp(a) reference measurement system: a pilgrimage to selective and accurate apo(a) quantification

  2023 Critical Reviews in Clinical Laboratory Sciences review Medicine Lipoproteins and Cardiovascular Health Open access

  44

  citations
• Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

  2021 Laboratory Service article Medicine Lipoproteins and Cardiovascular Health

  13

  citations
• Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial

  2020 European Heart Journal article Medicine Lipoproteins and Cardiovascular Health Open access cited by 2 patents

  221

  citations
• Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

  2020 Atherosclerosis article Medicine Lipoproteins and Cardiovascular Health Open access

  240

  citations
• Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

  2020 Journal of the American College of Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access cited by 1 patent

  604

  citations

6 results